Last reviewed · How we verify

NCT04827238

Standardized Invasive Hemodynamics for Elevated Gradients Post TAVR (DISCORDANCE TAVR)

Completed Last updated 24 July 2025
What this trial tests

trial testing Standardized Invasive Hemodynamics in Aortic Stenosis in 49 participants. Completed in 20 June 2025.

Timeline
30 August 2021
Primary endpoint
20 June 2025
20 June 2025

Quick facts

Lead sponsorUniversity of British Columbia
StatusCompleted
Study typeOBSERVATIONAL
Enrollment49
Start date30 August 2021
Primary completion20 June 2025
Estimated completion20 June 2025
Sites9 locations across Canada, United States

Drugs / interventions tested

Conditions studied

Sponsor

University of British Columbia

Who can join

Eligibility, any sex, with Aortic Stenosis or Aortic Valve Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The DISCORDANCE TAVR study will determine the discordance between echocardiography-derived and invasive transaortic gradients, as determined by a consistent and reproducible technique (Standardized Invasive Hemodynamics) post-TAVR.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Prognostic value of invasive versus echocardiography-derived aortic gradient in patients undergoing TAVI.
    van den Dorpel MMP, Chatterjee S, Adrichem R, Verhemel S, et al · · 2025 · cited 5× · PMID 40259836 · DOI 10.4244/eij-d-24-00341
  2. TAVI vs SAVR: The timeless showdown in aortic valve replacement.
    Baudo M. · · 2025 · PMID 39897417 · DOI 10.1016/j.ijcha.2025.101608

Verify or expand the search:

Other recruiting trials for Aortic Stenosis

Currently open trials in the same condition.

Other University of British Columbia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04827238.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing